Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays

Clinical and Vaccine Immunology

Volumn 17, Issue 9, 2010, Pages 1390-1397

  Brady, Rebecca A ^a   Verma, Anita ^a   Meade, Bruce D ^b   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Meade Biologics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SPECIES;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; PRIMATES; RABBITS; RECOMBINANT PROTEINS;

EID: 77956417668     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00145-10     Document Type: Article

References (30)

1. Abboud, N., and A. Casadevall. 2008. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin. Vaccine Immunol. 15:1115-1123.
2. Baillie, L. W. J. 2006. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 101:594-606.
3. Collier, R. J., and J. A. T. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
4. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
5. FDA. 2002. Transcripts of Workshop, Anthrax Vaccines: Efficacy Testing and Surrogate Markers of Immunity. http://www.fda.gov/cber/minutes/workshop-min. htm.
6. FDA. 2007. Transcripts of Workshop, Anthrax: Bridging Correlates of Protection in Animals to Immunogenicity in Humans. http://www.fda.gov/cber/ minutes/workshop-min.htm.
7. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. M. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
8. Flick-Smith, H. C., J. E. Eyles, R. Hebdon, E. L. Waters, R. J. Beedham, T. J. Stagg, J. Miller, H. O. Alpar, L. W. J. Baillie, and E. D. Williamson. 2002. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70:2022-2028.
9. Flick-Smith, H. C., N. J. Walker, P. Gibson, H. Bullifent, S. Hayward, J. Miller, R. W. Titball, and E. D. Williamson. 2002. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70:1653-1656.
10. Friedlander, A. M., S. L. Welkos, and B. E. Ivins. 2002. Anthrax vaccines. Curr. Top. Microbiol. Immunol. 271:33-60.
11. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82-87.
12. Grabenstein, J. D. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46:129-136.
13. Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784.
14. Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhuis, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, and J. L. Gerberding. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.
15. Lacy, D. B., D. J. Wigelsworth, R. A. Melnyk, S. C. Harrison, and R. J. Collier. 2004. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Nat. Acad. Sci. U. S. A. 101:13147-13151.
16. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715.
17. Mandel, M., and A. Higa. 1970. Calcium-dependent bacteriophage DNA infection. J. Mol. Biol. 53:159-162.
18. Miller, J., B. W. McBride, R. J. Manchee, P. Moore, and L. W. Baillie. 1998. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett. Appl. Microbiol. 26:56-60.
19. Ngai, P. K., F. Ackermann, H. Wendt, R. Savoca, and H. R. Bosshard. 1993. Protein A antibody-capture ELISA (PACE): an ELISA format to avoid denaturation of surface-adsorbed antigens. J. Immunol. Methods 158:267-276.
20. Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385: 833-838.
21. Phipps, A. J., C. Premanandan, R. E. Barnewall, and M. D. Lairmore. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 68:617-629.
22. Pitt, M. L. M., S. Little, B. E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A. M. Friedlander. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87:304.
23. Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972-978.
24. Reason, D., J. Liberato, J. Y. Sun, W. Keitel, and J. H. Zhou. 2009. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect. Immun. 77:2030-2035.
25. Reason, D. C., A. Ullal, J. Liberato, J. Sun, W. Keitel, and J. Zhou. 2008. Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine 26:4041-4047.
26. Rosenthal, S. R., and J. C. Clifford. 2002. Development of vaccines for bio-warfare agents. Dev. Biol. (Basel) 110:99-105.
27. Schwab, C., and H. R. Bosshard. 1992. Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies. J. Immunol. Methods 147:125-134.
28. Verma, A., M. M. Ngundi, B. D. Meade, R. De Pascalis, K. L. Elkins, and D. L. Burns. 2009. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin. Vaccine Immunol. 16:1405-1412.
29. Williamson, E. D., I. Hodgson, N. J. Walker, A. W. Topping, M. G. Duchars, J. M. Mott, J. Estep, C. LeButt, H. C. Flick-Smith, H. E. Jones, H. Li, and C. P. Quinn. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73:5978-5987.
30. Zhou, J., A. Ullal, J. Liberato, J. Sun, W. Keitel, and D. C. Reason. 2008. Paratope diversity in the human antibody response to Bacillus anthracis protective antigen. Mol. Immunol. 45:338-347.